News & Updates

Researchers Discover Hidden SARS-CoV-2 ‘Gate’ That Opens to Allow COVID Infection

08/26/2021

Excerpt from the Press Release: Since the early days of the COVID pandemic, scientists have aggressively pursued the secrets of the mechanisms that allow severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter and infect healthy human cells. Early in the pandemic, University of California San Diego’s Rommie Amaro, a computational biophysical chemist, helped develop…

Read More

Privo Technologies Named Winner of AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition

08/26/2021

Excerpt from the Press Release: PEABODY, Mass., Aug. 19, 2021 /PRNewswire/ — Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal cancers, announced today that Privo and its CEO, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition. Privo was selected from…

Read More

Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.

08/26/2021

Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc. Oncology Pharma will pursue the early feasibility and nonclinical development of a dactinomycin nanoemulsion drug product intended for the treatment of…

Read More

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

08/25/2021

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Aug. 19, 2021– Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that new data show the company’s cerebrospinal fluid assay, CNSide™, detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis, allowing for targeted treatment decisions that may improve outcomes…

Read More

AGTC Appoints Ophthalmology and Retinal Disease Specialist and Industry R&D Veteran Yehia Hashad, MD to its Board of Directors

08/25/2021

Excerpt from the Press Release: GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced the addition of Yehia Hashad, MD to its Board of Directors.…

Read More

Pluto Biosciences Launches Cloud-based Collaborative Life Sciences Platform for Academia, Biotech and Pharma Organizations

08/25/2021

Excerpt from the Press Release: Pluto Biosciences, a biotech software startup, launched its cloud-based, collaborative life sciences platform that leverages technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University. The Pluto platform simplifies secure, collaborative data sharing and bioinformatics analysis for academic, biotech, and pharmaceutical organizations. The Pluto platform was built to…

Read More

Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates

08/24/2021

Excerpt from the Press Release: PRINCETON, N.J., Aug. 18, 2021 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive data demonstrating the efficacy of multiple filovirus vaccine candidates in NHPs, including thermostabilized multivalent vaccines…

Read More

Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

08/24/2021

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced it has selected a fourth core inhibitor candidate, ABI-4334 (4334), that has been optimized for potency, to advance into clinical development.…

Read More

Peptilogics and Cerebras Systems Partner on AI Solutions to Advance the Future of Peptide Therapeutics

08/24/2021

Excerpt from the Press Release: SUNNYVALE, Calif. & PITTSBURGH, Pa.–(BUSINESS WIRE)–Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras…

Read More

Gritstone secures CEPI funding to test Covid vaccine; first focus is South Africa

08/23/2021

Excerpt from the Press Release: Gritstone bio is developing Covid-19 vaccines that use self-amplifying messenger RNA, which is intended to further boost the immune response compared to mRNA alone. The company also says its vaccine candidates may be able to protect against variants of the novel coronavirus. As coronavirus variants continue to fuel the ongoing…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives